An official website of the United States government
Home
Name
Vemurafenib
Alternate Names
PLX4032
Zelboraf
Abbreviations
None
Category
Chemotherapy
Subcategory
Kinase Inhibitor
NSC Number
None
Primary Site
None
Histology
None
Remarks
Received FDA approval 8/17/2011for treatment of metastatic melanoma with BRAF mutation as detected by a FDA approved test.
November 6, 2017: The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
October 2023: Zelboraf in combination with cobimetinib (Cotellic) is currently in trials for treatment of craniopharyngioma. This drug combination has not received FDA approval but may been in use in patient care out-side of trials.
November 6, 2017: The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
October 2023: Zelboraf in combination with cobimetinib (Cotellic) is currently in trials for treatment of craniopharyngioma. This drug combination has not received FDA approval but may been in use in patient care out-side of trials.
Coding
This drug should be coded
